share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bozic Carmen

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bozic Carmen

福泰製藥 | 4:持股變動聲明-高管 Bozic Carmen
美股SEC公告 ·  07/12 16:12
Moomoo AI 已提取核心訊息
Vertex Pharmaceuticals Inc. EVP and CMO, Carmen Bozic, completed a sale of 2,280 shares of company stock on July 10, 2024. The transaction was executed at a price of $487.34 per share, resulting in a total sale value of approximately $1,111,135. Following the sale, Bozic's direct holdings in Vertex Pharmaceuticals total 27,819 shares. The sale took place through an open market transaction, as reported in the company's latest filing.
Vertex Pharmaceuticals Inc. EVP and CMO, Carmen Bozic, completed a sale of 2,280 shares of company stock on July 10, 2024. The transaction was executed at a price of $487.34 per share, resulting in a total sale value of approximately $1,111,135. Following the sale, Bozic's direct holdings in Vertex Pharmaceuticals total 27,819 shares. The sale took place through an open market transaction, as reported in the company's latest filing.
福泰製藥公司執行副總裁兼首席醫療官卡門·博齊克(Carmen Bozic)於2024年7月10日出售了2280股公司股票。交易價格爲每股487.34美元,總銷售價值約爲1111135美元。在出售後,博齊克在福泰製藥的直接持股總數爲27819股。該銷售是通過公開市場交易完成的,如公司的最新報告所述。
福泰製藥公司執行副總裁兼首席醫療官卡門·博齊克(Carmen Bozic)於2024年7月10日出售了2280股公司股票。交易價格爲每股487.34美元,總銷售價值約爲1111135美元。在出售後,博齊克在福泰製藥的直接持股總數爲27819股。該銷售是通過公開市場交易完成的,如公司的最新報告所述。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息